Taxus Cardium Pharmaceuticals Group (CRXM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,736 | -5,179 | -1,730 | -1,040 | -11,681 |
| Depreciation Amortization | 180 | 124 | 82 | 40 | 6,223 |
| Accounts receivable | 115 | 115 | 115 | 115 | 83 |
| Accounts payable and accrued liabilities | -1,703 | -1,493 | -1,294 | -725 | -1,259 |
| Other Working Capital | -1,201 | -1,169 | -681 | -605 | -1,911 |
| Other Operating Activity | -70 | 1,623 | -293 | 293 | -3,070 |
| Operating Cash Flow | $-7,414 | $-5,978 | $-3,801 | $-1,921 | $-11,614 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -52 | -33 | -31 | -11 | N/A |
| Purchase Sale Intangibles | -65 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -65 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $-117 | $-33 | $-31 | $-11 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 3,966 |
| Debt Repayment | N/A | 0 | 0 | N/A | -10,750 |
| Common Stock Issued | 10,812 | 10,348 | 10,393 | 10,384 | 10,434 |
| Other Financing Activity | 0 | 0 | 0 | 0 | 10,225 |
| Financing Cash Flow | $10,812 | $10,348 | $10,393 | $10,384 | $13,875 |
| Beginning Cash Position | 3,364 | 3,364 | 3,364 | 3,364 | 1,103 |
| End Cash Position | 6,644 | 7,701 | 9,926 | 11,816 | 3,364 |
| Net Cash Flow | $3,280 | $4,337 | $6,562 | $8,452 | $2,261 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,414 | -5,978 | -3,801 | -1,921 | -11,614 |
| Capital Expenditure | -52 | -33 | -31 | -11 | N/A |
| Free Cash Flow | -7,466 | -6,011 | -3,831 | -1,932 | -11,614 |